ADNI data is made available to researchers around the world. As such, there are many active research projects accessing and applying the shared ADNI data. To further encourage Alzheimer’s disease research collaboration, and to help prevent duplicate efforts, the list below shows the specific research focus of the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Jennifer Zimmer |
| Institution: | Eli Lilly & Company |
| Department: | Medicines Development Unit |
| Country: | |
| Proposed Analysis: | Access will be used to provide a summary of adverse event data, discontinuations, and deaths in ADNI participants, to provide background rates for ongoing clinical trials in patients with MCI and AD dementia. In 2012, Henley et al. manuscript Safety profile Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative an other 18-month studies was published (Alzheimer's & Dementia 2012(8) 407-416. This article was based on ADNI date through 5 Jan 2010. The proposed analysis will be based on updated ADNI data. |
| Additional Investigators | |
| Investigator's Name: | Scott Andersen |
| Proposed Analysis: | same as principle investigator's proposal |
| Investigator's Name: | john sims |
| Proposed Analysis: | same as principal investigator's proposed analysis |
